Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways

Sanna Maria Käkönen, Katri S. Selander, John Chirgwin, Juan Juan Yin, Suzanne Burns, Wayne A. Rankin, Barry G. Grubbs, Mark Dallas, Yong Cui, Theresa Guise

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Transforming growth factor (TGF)-β promotes breast cancer metastasis to bone. To determine whether the osteolytic factor parathyroid hormone-related protein (PTHrP) is the primary mediator of the tumor response to TGF-β, mice were inoculated with MDA-MB-231 breast cancer cells expressing a constitutively active TGF-β type I receptor. Treatment of the mice with a PTHrP-neutralizing antibody greatly decreased osteolytic bone metastases. There were fewer osteoclasts and significantly decreased tumor area in the antibodytreated mice. TGF-β can signal through both Smad and mitogen-activated protein (MAP) kinase pathways. Stable transfection of wild-type Smad2, Smad3, or Smad4 increased TGF-β-stimulated PTHrP secretion, whereas dominant-negative Smad2, Smad3, or Smad4 only partially reduced TGF-β-stimulated PTHrP secretion. When the cells were treated with a variety of protein kinases inhibitors, only specific inhibitors of the p38 MAP kinase pathway significantly reduced both basal and TGF-β-stimulated PTHrP production. The combination of Smad dominant-negative blockade and p38 MAP kinase inhibition resulted in complete inhibition of TGF-β stimulated PTHrP production. Furthermore, TGF-β treatment of MDA-MB-231 cells resulted in a rapid phosphorylation of p38 MAP kinase. Thus, the p38 MAP kinase pathway appears to be a major component of Smad-independent signaling by TGF-β and may provide a new molecular target for anti-osteolytic therapy.

Original languageEnglish (US)
Pages (from-to)24571-24578
Number of pages8
JournalJournal of Biological Chemistry
Volume277
Issue number27
DOIs
StatePublished - Jul 5 2002
Externally publishedYes

Fingerprint

Parathyroid Hormone-Related Protein
Transforming Growth Factors
Mitogen-Activated Protein Kinases
Neoplasm Metastasis
p38 Mitogen-Activated Protein Kinases
Tumors
Bone
Breast Neoplasms
Bone and Bones
Phosphorylation
Growth Factor Receptors
Osteoclasts
Protein Kinase Inhibitors
Neutralizing Antibodies
Transfection
Neoplasms
Cells

ASJC Scopus subject areas

  • Biochemistry

Cite this

Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. / Käkönen, Sanna Maria; Selander, Katri S.; Chirgwin, John; Yin, Juan Juan; Burns, Suzanne; Rankin, Wayne A.; Grubbs, Barry G.; Dallas, Mark; Cui, Yong; Guise, Theresa.

In: Journal of Biological Chemistry, Vol. 277, No. 27, 05.07.2002, p. 24571-24578.

Research output: Contribution to journalArticle

Käkönen, Sanna Maria ; Selander, Katri S. ; Chirgwin, John ; Yin, Juan Juan ; Burns, Suzanne ; Rankin, Wayne A. ; Grubbs, Barry G. ; Dallas, Mark ; Cui, Yong ; Guise, Theresa. / Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. In: Journal of Biological Chemistry. 2002 ; Vol. 277, No. 27. pp. 24571-24578.
@article{0626423fb4fe4ca4b3869f2198375283,
title = "Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways",
abstract = "Transforming growth factor (TGF)-β promotes breast cancer metastasis to bone. To determine whether the osteolytic factor parathyroid hormone-related protein (PTHrP) is the primary mediator of the tumor response to TGF-β, mice were inoculated with MDA-MB-231 breast cancer cells expressing a constitutively active TGF-β type I receptor. Treatment of the mice with a PTHrP-neutralizing antibody greatly decreased osteolytic bone metastases. There were fewer osteoclasts and significantly decreased tumor area in the antibodytreated mice. TGF-β can signal through both Smad and mitogen-activated protein (MAP) kinase pathways. Stable transfection of wild-type Smad2, Smad3, or Smad4 increased TGF-β-stimulated PTHrP secretion, whereas dominant-negative Smad2, Smad3, or Smad4 only partially reduced TGF-β-stimulated PTHrP secretion. When the cells were treated with a variety of protein kinases inhibitors, only specific inhibitors of the p38 MAP kinase pathway significantly reduced both basal and TGF-β-stimulated PTHrP production. The combination of Smad dominant-negative blockade and p38 MAP kinase inhibition resulted in complete inhibition of TGF-β stimulated PTHrP production. Furthermore, TGF-β treatment of MDA-MB-231 cells resulted in a rapid phosphorylation of p38 MAP kinase. Thus, the p38 MAP kinase pathway appears to be a major component of Smad-independent signaling by TGF-β and may provide a new molecular target for anti-osteolytic therapy.",
author = "K{\"a}k{\"o}nen, {Sanna Maria} and Selander, {Katri S.} and John Chirgwin and Yin, {Juan Juan} and Suzanne Burns and Rankin, {Wayne A.} and Grubbs, {Barry G.} and Mark Dallas and Yong Cui and Theresa Guise",
year = "2002",
month = "7",
day = "5",
doi = "10.1074/jbc.M202561200",
language = "English (US)",
volume = "277",
pages = "24571--24578",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "27",

}

TY - JOUR

T1 - Transforming growth factor-β stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways

AU - Käkönen, Sanna Maria

AU - Selander, Katri S.

AU - Chirgwin, John

AU - Yin, Juan Juan

AU - Burns, Suzanne

AU - Rankin, Wayne A.

AU - Grubbs, Barry G.

AU - Dallas, Mark

AU - Cui, Yong

AU - Guise, Theresa

PY - 2002/7/5

Y1 - 2002/7/5

N2 - Transforming growth factor (TGF)-β promotes breast cancer metastasis to bone. To determine whether the osteolytic factor parathyroid hormone-related protein (PTHrP) is the primary mediator of the tumor response to TGF-β, mice were inoculated with MDA-MB-231 breast cancer cells expressing a constitutively active TGF-β type I receptor. Treatment of the mice with a PTHrP-neutralizing antibody greatly decreased osteolytic bone metastases. There were fewer osteoclasts and significantly decreased tumor area in the antibodytreated mice. TGF-β can signal through both Smad and mitogen-activated protein (MAP) kinase pathways. Stable transfection of wild-type Smad2, Smad3, or Smad4 increased TGF-β-stimulated PTHrP secretion, whereas dominant-negative Smad2, Smad3, or Smad4 only partially reduced TGF-β-stimulated PTHrP secretion. When the cells were treated with a variety of protein kinases inhibitors, only specific inhibitors of the p38 MAP kinase pathway significantly reduced both basal and TGF-β-stimulated PTHrP production. The combination of Smad dominant-negative blockade and p38 MAP kinase inhibition resulted in complete inhibition of TGF-β stimulated PTHrP production. Furthermore, TGF-β treatment of MDA-MB-231 cells resulted in a rapid phosphorylation of p38 MAP kinase. Thus, the p38 MAP kinase pathway appears to be a major component of Smad-independent signaling by TGF-β and may provide a new molecular target for anti-osteolytic therapy.

AB - Transforming growth factor (TGF)-β promotes breast cancer metastasis to bone. To determine whether the osteolytic factor parathyroid hormone-related protein (PTHrP) is the primary mediator of the tumor response to TGF-β, mice were inoculated with MDA-MB-231 breast cancer cells expressing a constitutively active TGF-β type I receptor. Treatment of the mice with a PTHrP-neutralizing antibody greatly decreased osteolytic bone metastases. There were fewer osteoclasts and significantly decreased tumor area in the antibodytreated mice. TGF-β can signal through both Smad and mitogen-activated protein (MAP) kinase pathways. Stable transfection of wild-type Smad2, Smad3, or Smad4 increased TGF-β-stimulated PTHrP secretion, whereas dominant-negative Smad2, Smad3, or Smad4 only partially reduced TGF-β-stimulated PTHrP secretion. When the cells were treated with a variety of protein kinases inhibitors, only specific inhibitors of the p38 MAP kinase pathway significantly reduced both basal and TGF-β-stimulated PTHrP production. The combination of Smad dominant-negative blockade and p38 MAP kinase inhibition resulted in complete inhibition of TGF-β stimulated PTHrP production. Furthermore, TGF-β treatment of MDA-MB-231 cells resulted in a rapid phosphorylation of p38 MAP kinase. Thus, the p38 MAP kinase pathway appears to be a major component of Smad-independent signaling by TGF-β and may provide a new molecular target for anti-osteolytic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0037025352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037025352&partnerID=8YFLogxK

U2 - 10.1074/jbc.M202561200

DO - 10.1074/jbc.M202561200

M3 - Article

VL - 277

SP - 24571

EP - 24578

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 27

ER -